JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillis, A. M.
Right arrow Articles by Lester, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillis, A. M.
Right arrow Articles by Lester, W. M.

Vol. 292, Issue 1, 381-386, January 2000

Dispersion of Ventricular Repolarization and Ventricular Fibrillation in Left Ventricular Hypertrophy: Influence of Selective Potassium Channel Blockers1

Anne M. Gillis, Heather J. Mathison, Elzbieta Kulisz and Wanda M. Lester

The Cardiovascular Research Group, Departments of Medicine and Pathology, The University of Calgary, Calgary, Alberta, Canada

This study tested the hypothesis that combination ion channel blockers of the transient outward current (Ito) and the rapid component of the delayed rectifying current (IKr) would produce greater prolongation of the ventricular action potential duration (APD) and increased dispersion of the APD in hypertrophied hearts compared with control hearts. Isolated rabbit hearts were studied 48 ± 5 days postabdominal aortic banding. Left ventricular endocardial and epicardial APDs were significantly greater at baseline in the hypertrophied group than in controls (P < .05). The magnitude of APD prolongation induced by the Ito blocker 4-aminopyridine (4-AP) and combination 4-AP and the IKr blocker dofetilide was greater in the hypertrophied hearts than in the normal hearts (P < .01). Mean APD dispersion was significantly greater in the hypertrophied group than in the control hearts at baseline (P < .05). 4-AP increased APD dispersion by a similar magnitude in the hypertrophied hearts (10 ± 10 ms) and the control hearts (8 ± 8 ms, P = NS), whereas the combination 4-AP and dofetilide increased APD dispersion by a greater magnitude in the hypertrophied hearts (41 ± 28 ms) than the control hearts (21 ± 11 ms, P < .05). Ventricular fibrillation occurred spontaneously in four hypertrophied hearts (40%) during combination drug perfusion and in none of the control hearts (P < .05). Thus, combination Ito and IKr blockers cause greater prolongation APD and increased APD dispersion in left ventricular hypertrophy, and this is associated with the development of ventricular fibrillation.


1 This study was supported by the Medical Research Council of Canada. Dr. Gillis is a senior scholar of the Alberta Heritage Foundation for Medical Research.


0022-3565/0/2921-0381$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X.-S. Liu, M. Jiang, M. Zhang, D. Tang, H. F. Clemo, R. S. D. Higgins, and G.-N. Tseng
Electrical remodeling in a canine model of ischemic cardiomyopathy
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H560 - H571.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. M. Gillis, K. M. Kavanagh, H. J. Mathison, J. R. Somers, S. Zhan, and H. J. Duff
Heart block in mice overexpressing calcineurin but not NF-AT3
Cardiovasc Res, December 1, 2004; 64(3): 488 - 495.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Oikarinen, M. S. Nieminen, M. Viitasalo, L. Toivonen, S. Jern, B. Dahlof, R. B. Devereux, P. M. Okin, and for the LIFE Study Investigators
QRS Duration and QT Interval Predict Mortality in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study
Hypertension, May 1, 2004; 43(5): 1029 - 1034.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G.-X. Yan, S. J. Rials, Y. Wu, T. Liu, X. Xu, R. A. Marinchak, and P. R. Kowey
Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization
Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1968 - H1975.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
R. Wolk
Arrhythmogenic mechanisms in left ventricular hypertrophy
Europace, January 1, 2000; 2(3): 216 - 223.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.